Recommendations on the use of anticoagulants for the treatment of patients with heparin-induced thrombocytopenia in Switzerland.

Details

Serval ID
serval:BIB_3B9867E05FE6
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Recommendations on the use of anticoagulants for the treatment of patients with heparin-induced thrombocytopenia in Switzerland.
Journal
Swiss medical weekly
Author(s)
Alberio L., Angelillo-Scherrer A., Asmis L., Casini A., Fontana P., Graf L., Hegemann I., Kremer Hovinga J.A., Korte W., Lecompte T., Martinez M., Nagler M., Studt J.D., Tsakiris D.A., Wuillemin W.
ISSN
1424-3997 (Electronic)
ISSN-L
0036-7672
Publication state
Published
Issued date
20/04/2020
Peer-reviewed
Oui
Volume
150
Pages
w20210
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse drug effect that occurs in 0.1–5% of heparin treated patients. Management of acute HIT currently involves (1) cessation of heparin exposure, and (2) inhibition of coagulation with an anticoagulant other than heparin. Several anticoagulants can be considered for the treatment of HIT. Anticoagulant monitoring, management of drug-induced adverse events including bleeding, and therapeutic dosing schedules in selected clinical settings represent challenges to the clinician treating HIT patients. Moreover, the fact that not all registered anticoagulants are approved for HIT in Switzerland further complicates the management of HIT. The present recommendations on the anticoagulant treatment of HIT in Switzerland have been elaborated by a panel of Swiss experts belonging to the Working Party Hemostasis (WPH) of the Swiss Society of Hematology (SGH-SSH). They are intended to support clinicians in their decision making when treating HIT patients.
Pubmed
Open Access
Yes
Create date
02/05/2020 14:39
Last modification date
19/11/2020 6:26
Usage data